Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Lung
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Not Available
Horn, Leora
International
Vanderbilt University
04-25-2017
Treatment
VICCTHO1691
NCT02864992

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Signed, written informed consent by subject or legal representative prior to any trial-specific screening procedure

Male or female, greater than or equal to (>=) 18 years of age (or having reached the age of majority according to local laws and regulations

Measurable disease in accordance with RECIST version 1.1

Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

Not a woman of childbearing potential OR

A woman of childbearing potential who agrees to use a highly effective contraception

A male subject must agree to use and to have their female partners of childbearing potential to use a highly effective contraception

Histologically confirmed advanced (Stage IIIB/IV) Non-small Cell Lung Cancer NSCLC (all histologies including squamous and sarcomatoid)

Treatment naïve patients in first-line or pretreated patients with no more than 2 lines of prior therapy

Subjects with MET alterations, namely METex14 skipping alterations in plasma and/or tissue, or MET amplification only in plasma and/or tumor biopsy samplet



Exclusion Criteria:

Subjects with characterized Epidermal Growth Factor Receptor (EGFR) activating mutations that predict sensitivity to anti-EGFR-therapy

Subjects with characterized Anaplastic Lymphoma Kinase (ALK) rearrangements that predict sensitivity to anti-ALK therapy

Active brain metastases

Any unresolved toxicity Grade 2 or more according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) from previous anticancer therapy

Need for transfusion within 14 days prior to the first dose of trial treatment

Prior chemotherapy, biological therapy, radiation therapy, hormonal therapy for anti-cancer purposes, targeted therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of trial treatment;

Subjects who have brain metastasis as the only measurable lesion

Inadequate hematological, liver, renal, cardiac function

Prior treatment with other agents targeting the Hepatocyte Growth Factor c(HGF/c) -Met pathway

Hypertension uncontrolled by standard therapies (not stabilized to
Past or current history of neoplasm other than Non-small Cell Lung Cancer (NSCLC), except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years

Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the test product

Major surgery within 28 days prior to Day 1 of trial treatment

Known infection with human immunodeficiency virus, or an active infection with hepatitis B or hepatitis C virus

Substance abuse, active infection, or other acute or chronic medical or psychiatric condition or laboratory abnormalities that might increase the risk associated with trial participation at the discretion of Investigators

Known hypersensitivity to any of the trial treatment ingredients

Legal incapacity or limited legal capacity

Any other reason that, in the opinion of the Principal Investigator, precludes the subject from participating in the trial

Participation in another clinical trial within the past 30 days

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: